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Abstract
Objective: Recent studies indicate that the innate immune system is not only triggered by exogenous pathogens and
pollutants, but also by endogenous danger signals released during ischemia and necrosis. As triggers for the innate immune
NLRP3 inflammasome protein complex appear to overlap with those for cardiac ischemia-reperfusion (I/R) and ischemic
preconditioning (IPC), we explored the possibility that the NLRP3 inflammasome is involved in IPC and acute I/R injury of the
heart.
Principal Findings: Baseline cardiac performance and acute I/R injury were investigated in isolated, Langendorff-perfused
hearts from wild-type (WT), ASC2/2 and NLRP32/2 mice. Deletion of NLRP3 inflammasome components ASC2/2 or NLRP32/
2 did not affect baseline performance. The deletions exacerbated I/R-induced mechanical dysfunction, but were without
effect on I/R-induced cell death. When subjected to IPC, WT and ASC2/2 hearts were protected against I/R injury (improved
function and less cell death). However, IPC did not protect NLRP32/2 hearts against I/R injury. NLRP32/2 hearts had
significantly decreased cardiac IL-6 levels with a trend towards lower IL-1b levels at end reperfusion, suggesting abrogation
of IPC through diminished IL-6 and/or IL-1b signaling. Subsequent experiments showed that neutralising IL-6 using an
antibody against IL-6 abrogated IPC in WT hearts. However, inhibition of the IL-1r receptor with the IL-1 receptor inhibitor
Anakinra (100 mg/L) did not abrogate IPC in WT hearts. Analysis of survival kinases after IPC demonstrated decreased STAT3
expression in NLRP32/2 hearts when compared to WT hearts.
Conclusions: The data suggest that the innate immune NLRP3 protein, in an NLRP3-inflammasome-independent fashion, is
an integral component of IPC in the isolated heart, possibly through an IL-6/STAT3 dependent mechanism.
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Introduction
The innate immune system is the first line of defence against
stress signals such as exogenous pathogen-associated molecular
patterns (PAMPs) and pollutants. Intriguingly, recent data have
demonstrated that the innate immune system is also activated by
ischemia and necrosis through endogenous danger-associated
molecular patterns (DAMPs), the so-called sterile inflammatory
response [1]. Such DAMPs may entail uric acid, adenosine, ATP,
heat shock protein, HMGB1, DNA, or myosin released by
damaged cells [1–3]. Interestingly, it is suggested that these
DAMPs activate the cellular innate immune system through
trigger mechanisms involving potassium extrusion and radical
production [4], [5]. Exact similar trigger mechanisms are
implicated in cardiac ischemia-reperfusion (I/R) and ischemic
preconditioning (IPC) [6], suggesting that activation of the innate
immune system is maybe an intrinsic part of I/R and IPC
physiology. In the current work we examine to what extent the
NLRP3 inflammasome, a specific part of the innate immune
system, affects acute I/R and IPC cardiac physiology. Such
interrelationships between hypoxia, IPC and inflammation are
also well documented for other, non-inflammasome, parts of the
immune system, where hypoxia-induced hypoxia-inducible tran-
scription factor HIF modulates inflammation and IPC through
adenosine and NF-kB signaling [7], [8].
Innate immune responses are activated within minutes upon
encounter with DAMPs or PAMPs. Such receptors entail the well-
known Toll-like receptors (TLR), localized either at the cell surface
or within endosomes, and the nucleotide oligomerization domain
(Nod)-like receptors (NLRs), which are intracellular cytosolic
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sensors [9]. NLRP3 inflammasome, a member of the NLRs, is a
multiprotein complex consisting of NLRP3, along with ASC
(adapter apoptosis-associated speck-like protein containing a C-
terminal CARD) and caspase-1 [10]. Upon assembly, caspase-1 is
activated resulting in the processing and release of proinflamma-
tory cytokines among which the interleukin IL-1b figures
prominently [9].
The NLRP3 inflammasome is critically involved in the sterile
inflammatory response as reported for e.g. monocytes and
tumour cells [4], [10], [11]. In addition, it has recently been
shown that NLRP3 deficiency protects animals against renal
ischemic tubular necrosis [12]. Inflammation is also critically
involved in myocardial I/R injury, with a prominent role for IL-
1b as an early mediator of inflammation [13], [14]. Our first
goal is therefore to examine the role of the NLRP3 inflamma-
some in acute myocardial I/R injury, knowledge that is currently
missing in the literature. Conversely, IL-1b can indirectly
modulate IL-6 and TNF-alpha [15]. These inflammatory
mediators may also be protective, because they are able to
induce IPC [16], [17]. Moreover, mitochondrial signals [5], [6],
[12] seem to mediate both activation of the NLPR3 inflamma-
some and IPC protective effects in relation to I/R injury. It
therefore seems possible that NLRP3 inflammasome activation
may interact with IPC. To our knowledge, no information is
available whether the NLRP3 inflammasome is involved in IPC.
Our second goal is therefore to examine the role of the NLRP3
inflammasome in cardiac IPC. Finally, although initial research
has emphasized the importance of the formation of the
multiprotein complex NLRP3 inflammasome for their inflam-
matory effects, suggesting that the individual components only
exert its action through complex formation, very recent research
has indicated complex ( = inflammasome)-independent effects of
the separate components [18], [19]. Because such information is
currently lacking for cardiac I/R and IPC, we also addressed this
question through comparison of NLRP3 gene and ASC gene
knockout mice.
In this study we have investigated whether the NLRP3
inflammasome is involved in acute cardiac I/R injury and IPC,
and whether specific inflammatory pathways that are affected by
ablation of constituents (NLRP3 or ASC) of the assembled NLRP3
inflammasome are involved in observed changes in I/R and IPC.
Methods
Animals
C57BL/6J Nlrp32/2 and ASC2/2 mice were originally
obtained from dr RA Flavell (Yale University, New Haven, CT,
USA), and described before [20]. Both genotypes were back-
crossed with C57BL/6J background for at least 9 generations. The
wild-type (WT) mice in the present study were all C57BL/6J
obtained from Charles River. Experiments were performed with
male mice only. Mice were fed a standard chow (CRM(E) diet,
SDS, Witham, England) ad libitum and studied at 10–15 weeks of
age. All experiments were approved by the animal ethics
committee of the Academic Medical Center, Amsterdam, The
Netherlands.
Heart Perfusion
In vitro I/R protocol was performed as previously described
with slight modifications [21], [22]. Mice were heparinized (15 IU)
and anesthetized with Nembutal (80 mg kg21). Following trache-
otomy, the mice were mechanically ventilated and a thoracotomy
performed. The hearts were cannulated in situ with perfusion
started before excision of the heart. Hearts were Langendorff-
perfused at a constant flow (initial perfusion pressure 80 mm Hg)
at 37uC with Krebs-Henseleit solution containing (mmol l21) NaCl
118, KCl 4.7, CaCl2 2.25, MgSO4 1.2, NaHCO3 25, KH2PO4
1.2, EDTA 0.5 and glucose 11, gassed with 95% O2/5% CO2.
The perfusate was in-line filtered by a 0.45-mm filter. End-diastolic
pressure (EDP) was set at ,4–8 mmHg using a water-filled
polyethylene balloon inserted into the left ventricular (LV) cavity
via the mitral valve. The hearts were continuously submerged in
37uC perfusate. LV developed pressure was calculated as the
systolic pressure (Psys) minus EDP. The rate-pressure product
(RPP, index of mechanical performance)) was the product of the
developed LV pressure and the heart rate. Following 20 min
stabilization of LV pressure, all hearts were subjected to 35 min of
perfusion with or without IPC, followed by 35 min no-flow
ischemia and 45 min reperfusion. During ischemia, the hearts
were submerged in Krebs-Henseleit perfusate gassed with 95%
N2/5% CO2. The IPC protocol consisted of 3 times 5 min
ischemia followed by 5 min reperfusion for the first two times of
5 min I, and 10 min reperfusion following the last 5 min I, before
the 35 min of I.
In the first series of experiments, six different groups of hearts
(n = 7 each) were studied consisting of WT, ASC2/2 and
NLRP32/2 genotypes, with each genotype subjected to either I/
R only or to I/R plus IPC.
In the second series of experiments, two groups were examined
(n= 7 each) to explore potential NLRP3 cytokine-related pathways
in IPC. In the first group, WT hearts were continuously exposed
from the start of the experiment to 100 mg/L Anakinra (Kineret,
Biovitrum; an interleukin 1 receptor (IL-1 RA) inhibitor during
IPC, to examine a possible role for IL-1 signaling in acute IPC. In
the second group, WT hearts were continuously exposed from the
start of the experiment to 50 ng/ml anti-mouse IL-6 antibody
(R&D systems), to neutralize a possible role for IL-6 release and
signalling in IPC.
At the end of these experiments, hearts were weighed and
immediately homogenized in 1.5 ml homogenization medium (in
mM: 250 sucrose, 20 Hepes (pH 7.4), 10 KCl, 1.5 MgCl2, 1
EDTA, 0.1 PMSF, 5 mg/ml leupeptin, 5 mg/ml aprotinin and
1 mg/ml pepstatin). Homogenates were frozen at 280uC until
further analysis for cytokines and mRNA expression levels.
Finally, in a third series of experiments, two additional groups
(n = 4 each) were studied, to examine whether IPC in NLRP32/2
hearts was associated with alterations in well-known cardiopro-
tective survival pathways. To this end, isolated hearts from WT
and NLRP32/2 animals were subjected to IPC and global
ischemia as described above. At 5 min reperfusion hearts were
immediately freeze-clamped and stored at 280uC until further
analysis of survival kinases.
Lactate Dehydrogenase Enzyme Activity in Effluent
During the reperfusion period the effluent was collected at 5, 10,
15, 30 and 45 min of reperfusion and immediately frozen at
280uC. Lactate dehydrogenase (LDH) activity was determined
using standard spectrophotometric analysis at 340 nm [23]. LDH
release is used as index of necrosis, as other studies have shown a
good correlation between LDH release and TTC staining [24,25].
Cytokine Determination in Hearts
Homogenate was treated with 0.5% Triton X-100 for 10 min,
centrifuged at 10,000 g for 1 min and supernatant was used for
further analysis. Cytokines were determined in the supernatant by
ELISA: TNF-a (Quantikine Mouse TNF-a, R&D systems), IL-1b
(Quintikine Mouse IL-1b, R&D systems) and IL-6 (Duoset Mouse
NALP3 and Preconditioning
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IL-6, R&D systems). Results are normalized to protein content
determined by the Bradford method.
HMGB1 mRNA Expression Analysis in Hearts
Homogenate was treated with 0.5% Triton X-100 for 10 min,
centrifuged at 10,000 g for 1 min and supernatant was used for
further analysis. Total RNA was extracted from heart tissue with
Trizol reagent (Invitrogen) according to the manufacturer’s
protocol. All RNA samples were quantified by spectrophotometry
and stored at 280uC until processed for reverse transcription.
RNA was converted to cDNA by using oligo-dT as primer. High
mobility group box (HMGB)1 mRNA expression was analyzed by
RT-PCR performed on a Roche light cycler with SYBR green
PCR master mix. Specific gene expression was normalized to
mouse peptidylpropyl isomerase A (PPIA) gene expression. SYBR
green dye intensity was analyzed with linear regression analysis.
Primer sequences (Biolegio) were as follows: PPIA forward primer,
59-tgccagggtggtgactttac; reverse primer, 59-gatgccaggacctgtatgct;
HMGB1 forward primer, 59-gagagatgtggaacaacactgc; reverse
primer, 59-ctgtaggcagcaatatccttctc.
Survival Kinases in Preconditioned, Reperfused Hearts
Total heart homogenate was obtained by grinding a snap-frozen
heart in liquid nitrogen into powder, followed by homogenization
on ice in 1.5 ml homogenate buffer (in mM: 20 Hepes (pH 7.4),
70 NaCl, 2.5 MgCl2, 1 EDTA, 0.1 PMSF, 0.5% Triton, 0.1
PMSF, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mg/ml pepstatin
and phosphatase inhibitors. The homogenate was kept on ice for
60 min with intermittent vortex mixing. Finally, the mixture was
homogenized again on ice, and stored at 280uC. Equal amounts
of homogenate protein were electrophoresed on a precast gels (4–
12% Bis-Tris, Criterion XT, Bio-Rad), and transferred to an
Immobilon-FL Membrane (Type PVDF, pore size 0.45mm,
Millipore). The membranes were blocked with ready to use
blocking buffer (#927-40000, Li-Cor) for 1 hour. To detect
phosphorylated proteins, the membranes were incubated at 4uC
overnight with antibodies against pSTAT3 (Tyr 705) (1:500; Cell
Signaling), pAMPKa (1:2500; Cell Signaling), p-p44/42 MAP
kinase (1:5000; Cell Signaling) and pPKCe (1:2500; Bio connect).
Table 1. Physiological characteristics of Langendorff-perfused hearts of wild-type (WT), ASC2/2 and NLRP32/2 mice.
Flow (ml/min/g) EDP (mm Hg) Psys (mm Hg) HR (beats/min) RPP (103 mmHg/min)
WT 14.460.7 6.160.5 11862 376611 42.061.6
ASC2/2 14.361.4 5.760.4 11964 370614 42.362.4
NLRP32/2 13.861.6 6.460.6 11763 35969 39.761.5
Values are given as (mean 6 SEM). EDP: end-diastolic pressure; Psys: peak systolic pressure; HR: heart rate; RPP: rate-pressure-product.
doi:10.1371/journal.pone.0040643.t001
Figure 1. Ablation of NLRP3, but not ASC, abrogated IPC
protective effects on cardiac function following I/R. Effect of ASC
and NLRP3 gene ablation on cardiac mechanical performance following
acute I/R with or without preceding IPC in isolated perfused mouse
hearts. (A) End-diastolic pressure (EDP) measured at end reperfusion for
the different groups; (B) % Rate-pressure product (RPP) determined at
end reperfusion and normalized to baseline, pre-ischemic, values for the
different groups. Black bars denote I/R groups, white bars reflect IPC + I/
R groups. (n = 7 for all groups). Mean 6 SEM, * P,0.05 vs. I/R in WT, #
P,0.05 IPC+I/R vs. I/R similar group (ANOVA).
doi:10.1371/journal.pone.0040643.g001
Figure 2. Ablation of NLRP3, but not ASC, abrogated IPC
protective effects on cardiac I/R-induced cell death. Effects of
ASC and NLRP3 gene ablation on cell death (LDH enzyme release) after
I/R with or without preceding IPC. Accumulative LDH release during
45 min reperfusion is given for the different groups. Black bars denote
I/R groups, white bars reflect IPC + I/R groups. (n = 7 for all groups).
Mean 6 SEM, * P,0.05 vs. I/R in WT, # P,0.05 IPC+I/R vs. I/R similar
group (ANOVA).
doi:10.1371/journal.pone.0040643.g002
NALP3 and Preconditioning
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40643
To detect total proteins, the membranes were incubated at 4uC
overnight with antibodies against STAT3 (1:1000; Cell Signaling),
AMPKa (1:5000; Cell Signaling), p44/42 MAP kinase (1:10000;
Cell Signaling), against PKCe (1:5000; Bio connect), and against
a-tubulin (1:20000; Sigma). After washing 36with PBS with 0.1%
Tween 20, membranes were incubated for 1 hour with secondary
antibodies labelled with IRDye infrared dyes. Following washing,
membranes were analyzed with the Odyssey Infrared Imaging
System (Li-Cor). Densities of survival proteins were normalized to
the density of a-tubulin.
Statistical analysis. Data are presented as means 6 SE.
Data were analyzed ANOVA followed by Fisher’s post hoc tests.
Values of P,0.05 were considered to be statistically significant.
Results
Genetic manipulations of the NLRP3 inflammasome compo-
nents were without effect on baseline cardiac physiological
parameters of the isolated heart (table 1). No differences in the
RPP or flow were found in the conglomerate of HR and peak
developed LV pressure, indicating that basal work performed by
the hearts was not affected by deletion of the NLRP3 or ASC
component of the NLRP3 inflammasome.
To evaluate I/R-induced lethal injury, we examined three
classical parameters for lethal injury, i.e. contracture ( = EDP of
the heart), mechanical performance ( = RPP) and cell death
(release of the enzym lactate dehydrogenase in the effluent). The
I/R intervention resulted in 5064 mm Hg EDP (Fig. 1A) and
3564 % recovery of the RPP (Fig. 1B) in WT hearts at the end of
45 min reperfusion. To examine whether NLRP3 inflammasome
components ASC and NLRP3 affected I/R-induced mechanical
dysfunction, ASC2/2 and NLRP32/2 hearts were also subjected
to I/R and compared to WT hearts. ASC2/2 hearts showed
increased I/R injury on these functional cardiac parameters as
compared to WT hearts: EDP was increased to 6662 mm Hg,
and RPP recovery decreased to 1263%. The NLRP32/2 hearts
only demonstrated increased I/R-induced contracture
(6363 mmHg) as compared to WT hearts, without affecting
RPP recovery. We conclude that both the ASC and NLRP3
component of the NLRP3 inflammasome complex contribute to
improved heart function immediately following an I/R insult.
Next we examined whether the NLRP3 components affected
the IPC-protective effects on mechanical function following I/R as
observed in WT hearts (Fig. 1A and 1B). IPC significantly
Figure 3. Reduced IL-6 cytokine levels in reperfused NLRP32/2
hearts. Myocardial cytokine levels at end reperfusion for wild-type
(WT), ASC2/2 and NLRP32/2 hearts subjected to I/R with or without IPC.
IL-6 (A), TNF-a (B) and IL-1b (C) are given. Black bars denote I/R groups,
white bars reflect IPC + I/R groups. (n = 7 for all groups). Mean 6 SEM, *
P,0.05 vs. I/R in WT (ANOVA).
doi:10.1371/journal.pone.0040643.g003
Figure 4. Neutralizing IL-6, but not inhibition of IL-1r receptor,
prevented IPC protection in wild-type hearts. Effect of inhibition
of IL-1R receptor and neutralization of IL-6 on cardioprotective effect of
IPC in WT hearts. IPC protective effects were evaluated for EDP (A), RPP
(B) and LDH release during reperfusion (C). (n = 7 for all groups). Mean
6 SEM, * P,0.05 WT+I/R+IPC+inhibition vs. WT+I/R (ANOVA).
doi:10.1371/journal.pone.0040643.g004
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improved cardiac function following I/R in WT hearts, as
demonstrated by diminished EDP and improved RPP recovery
at end reperfusion. IPC was similarly effective in ASC2/2 hearts
as in WT hearts, improving both EDP and RPP. Surprisingly, IPC
was without effect on these parameters for the NLRP32/2 hearts,
indicating disrupted IPC signaling in these hearts. These data thus
demonstrated that the NLRP3 component of the NLRP3
inflammasome is necessary for IPC protective effects on heart
function, whereas the ASC component is not.
Subsequently, we examined whether the inflammasome com-
ponents affected I/R and IPC effects on cardiac cell death. LDH
release during reperfusion was used as index of cell death (Fig. 2).
Thirty-five minutes of ischemia resulted in a large release of LDH
during reperfusion for WT hearts. A similar release of LDH was
observed for ASC2/2 and NLRP32/2 hearts, indicating that
deletion of these NLRP3 inflammasome components does not
affect acute cell death induced by I/R. IPC significantly reduced
LDH release in WT (245%) and in ASC2/2 (233%) hearts.
However, IPC had no effect on LDH release in NLRP32/2
hearts. Thus, although both ASC and NLRP3 protein do not
affect I/R-induced cell death, the NLRP3 protein is necessary for
IPC protective effects on cardiac cell death.
Cytokines may be considered as inducers of IPC, in that small
increases in cytokines can activate cardiac intrinsic mechanisms
against I/R injury. To examine whether reduced cytokine levels
were associated with the reduced IPC in NLRP32/2 hearts,
cytokine levels were determined in the reperfused WT, ASC2/2
and NLRP32/2 - heart (Figure 3). Deletion of the ASC
component had no effect on myocardial tissue levels of IL-6
(Fig. 3A), TNF-a (Fig. 3B) or IL-1b (Fig. 3C). Deletion of NLRP3
resulted in significantly decreased myocardial IL-6 levels and in a
non-significant trend in decreased IL-1b levels. Ischemic precon-
ditioning was without significant effects on any of the cytokine
levels in the reperfused heart, despite a non-significant trend for
decreased TNF-a levels in WT hearts. These data therefore show
associations between reduced IPC and reduced cardiac IL-6 and
IL-1b levels in NLRP32/2 hearts.
To explore whether the observed directional decreased IL-1b
and IL-6 levels in the NLRP32/2 hearts may explain the IPC
abrogation in NLRP32/2 hearts, IPC was studied in WT hearts
during inhibition of these pathways. To inhibit IL-1b signaling, the
IL-1b membrane receptor IL-1R was inhibited through contin-
uous perfusion with the IL-1RA Anakinra. However, IPC was still
effective during IL-1R inhibition, neglecting an effect of IL-1R
signaling in acute cardiac IPC. IPC + Anakinra decreased EDP
(Fig. 4A), improved RPP recovery (Fig. 4B) and decreased LDH
release during reperfusion (Fig. 4C) in WT hearts vs. I/R-only WT
hearts.
To inhibit IL-6 signaling in WT hearts, IL-6 was neutralized
through continuous perfusion with the anti-IL-6 antibody
throughout the experiment. This treatment abrogated IPC: no
improvement in EDP, RPP recovery or LDH release was observed
(Fig. 4). The data demonstrate that IL-6 signaling is mandatory in
IPC, and raise the possibility that diminished IL-6 signaling
abrogates IPC in NLRP32/2 hearts.
To further explore the possible cellular mechanisms of
diminished IPC in NLRP32/2 hearts, we determined HMGB1
mRNA levels in reperfused hearts. HMGB1 was reported as a
preconditioning stimulus and was released in an inflammasome-
dependent fashion [26]. However, no differences in HMBG1
mRNA levels in the reperfused hearts were observed between
groups (Fig. 5), negating a role for HMGB1 in the attenuated IPC
response in NLRP32/2 hearts.
Finally, in a separate series of experiments we examined several
survival kinases that have been associated with cardioprotection by
IPC (Fig. 6). No differences in phosphorylation status of any of the
survival kinases between preconditioned WT and NLRP32/2
hearts at 5 min reperfusion were observed. There was a small
increase in AMPK expression in NLRP32/2 hearts versus WT
hearts. The largest effect of NLRP3 gene knockout was however
the diminished amount of STAT3 protein expression in precon-
ditioned hearts, as compared to WT preconditioned hearts. The
diminished STAT3 content, together with the reduced IL-6
content, suggest that the cardioprotective IL-6/STAT3 signaling
pathway is reduced in the NLRP32/2 hearts.
Discussion
In this study we have demonstrated that the intracellular innate
immunity NLRP3 component of the NLRP3 inflammasome is a
required component of IPC in the heart. This role of NLRP3 in
cardiac IPC is independent of the activation of the NLRP3
inflammasome, because ablation of the ASC-component of the
NLRP3 inflammasome was without effects on IPC. In addition,
our data suggest that the NLRP3-mediated cardioprotection is not
transduced through extracellular IL-1b signaling, the cytokine that
is most frequently associated with the NLRP3 inflammasome, but
most likely through extracellular IL-6 signaling. Finally, the
abolished IPC potential of NLRP32/2 hearts was associated with
a small increase in AMPK protein expression and a diminished
expression of the survival kinase STAT3 in reperfused hearts.
The innate immune system consists of so-called pathogen
recognition receptors that can be grouped in TLRs and NLRs [7].
Several studies have clearly demonstrated a role for TLRs in
cardiac I/R injury, by showing that TLR deficiency resulted in
diminished I/R injury [27]. However, a possible role for TLR in
IPC has received much less attention. Only recently it has been
shown that myocardial IPC requires TLR2 (but not TLR4) [28].
Our study shows for the first time that myocardial IPC also
requires NLR. In contrast to TLR ablation, ASC or NLRP3
ablation did not result in diminished acute I/R-induced cell death.
Cardiac functional recovery (RPP) was even partly decreased with
ASC or NLRP3 ablation, suggesting divergent effects of the NLR
constituents versus the TLR constituents of the innate immune
Figure 5. Unaltered HMGB1 mRNA levels. Myocardial HMGB1
mRNA levels at end reperfusion for wild-type (WT), ASC2/2 and
NLRP32/2 hearts subjected to ischemia-reperfusion with or without IPC.
Black bars denote I/R groups, white bars reflect IPC + I/R groups. (n = 7
for all groups). Mean 6 SEM, * P,0.05 vs. I/R in WT (ANOVA).
doi:10.1371/journal.pone.0040643.g005
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pathway on cardiac I/R injury. However, our finding that NLRP3
is required for IPC cardioprotective effects is similar to the
observation that TLR2 is needed for IPC [25]. Interestingly, only
ablation of the NLRP3-component of NLRP3 inflammasome
abrogated IPC, whereas ablation of the ASC-component of the
NLRP3 inflammasome was without effect on IPC. It thus seems
that it is a NLRP3 inflammasome-independent mechanism that is
involved in cardiac IPC. Other recent reports [18], [19] support
our observation that NLRP3 and ASC, both being crucial
components of the so-called NLRP3 inflammasome protein
complex, may affect cellular biology through inflammasome-
independent mechanisms.
The significant decrease in IL-6 levels, which we have found in
our NLRP32/2 hearts, suggests IL-6 production to be, at least
partly, regulated by NLRP3. We are unaware of other studies that
have reported on IL-6 being dependent on NLRP3. As IL-18 was
reported to induce IL-6 production, it is possible that diminished
IL-18 in the NLRP32/2 hearts mediated the lower IL-6 content
Figure 6. Decreased STAT3 and increased AMPK protein levels in NLRP32/2 hearts. Effect of NLRP3 gene ablation on survival kinases and
their phosphorylation status in preconditioned hearts analyzed at 5 min reperfusion following 35 min ischemia. PKC-e (A), ERK (C), AMPK (E) and
STAT3 (G), and their phosphorylation status (B, D, F, and H, respectively) are shown (n = 4 hearts per genotype). Mean 6 SEM, *P,0.05 WT vs.
NLRP32/2.
doi:10.1371/journal.pone.0040643.g006
NALP3 and Preconditioning
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[29]. Further studies will be necessary to delineate this association
between NLRP3 and IL-6 cytokines at tissue levels. Most
importantly, the similar myocardial IL-1b levels among
NLRP32/2 and WT hearts, together with the observation that
inhibition of the IL-1b receptor with recombinant IL-1RA did not
prevent IPC in WT hearts, makes it unlikely that the loss of IPC in
the NLRP32/2 hearts can be explained by differences in IL-1b
signaling. In contrast, the decrease in myocardial IL-6 in
NLRP32/2 hearts together with the loss of IPC effects in WT
hearts with a neutralizing antibody against IL-6, strongly suggest
IL-6 to be the mediator of NLRP32/2 -induced lost of IPC.
Although it is known that IL-6 is an integral part of the TNF-a/
IL-1 cytokine signaling network [15], that TNF-a is involved in
classical IPC [17], and that IL-6 plays an obligatory role in
delayed preconditioning [16], we are unaware of studies that have
demonstrated directly a role of IL-6 in early IPC of the heart. We
now extend these discovered cardioprotective effects of IL-6 to
early IPC, demonstrating that neutralizing IL-6 mitigates early
IPC effects in WT hearts. Similar effects of IL-6 during IPC were
recently observed in a model of hepatic ischemia-reperfusion [30].
Although in the current study IL-6 was not measured in the
perfusate, other studies have shown that IPC can acutely increase
tissue IL-6 mRNA and protein levels [16], [30]. Similar effects
have been published for the cardioprotective cytokine TNF-a,
which was acutely increased in plasma during the IPC-stimulus
[31]. Interestingly, IL-6 has recently been indicated as a potential
mediator of remote IPC [32], a cardioprotective intervention with
demonstrated clinical benefits [33–35]. IL-6 binds to the
transmembrane IL-6 receptor that is part of the larger gp130,
which functions as a receptor subunit and signal transducer.
Gp130 is involved in two major signaling pathways: the JAK/
STAT3 and the SHP2-Erk-MAPK pathway [36]. Activation of
the STAT3 pathway is now known to exert major cardioprotective
effects against I/R injury, and is required in both early and
delayed preconditioning schemes [37], [38]. Our analysis of
survival kinases demonstrated that the abrogated IPC-effects in the
NLRP32/2 hearts was associated with reduced STAT3 protein
expression, at least suggesting that reduced signaling through this
IL-6/STAT3 pathway is a likely candidate to explain the reduced
IPC-protective effects in NLRP32/2 hearts. Interestingly, recent
studies have demonstrated that IL-6 is a potent activator of
STAT3, providing a direct link between this pro-inflammatory
cytokine IL-6 and STAT3 [39], [40]. The observed reduced
amount of STAT3 in NLRP32/2 hearts may also have its
implications for other studies using these mice, provided that
STAT3 is also reduced in other organs/tissues of NLRP32/2
animal.
A potential limitation of the use of the NLRP3 and ASC germ
line knockout strains, is that from these presented data we cannot
exclude the possibility of partial functional redundancy of Nlrp3 or
ASC with other inflamasome componens like e.g. NLRP4 and
others. These data could also indicate that Nlrp3 may have some
functional redundancy. Future studies of double and triple
knockout animals may be of value in addressing these issues. A
further limitation of our present study is its ex vivo nature,
excluding the possibility of studying effects of NLRP3/ASC
ablation on acute cardiac I/R and IPC through blood borne
components such as e.g. leucocytes. However, such an approach
will also allow dissection of organ intrinsic regulatory mechanisms
concerning I/R injury relative to effects mediated through
interaction with blood-born components derived from e.g. bone-
marrow, ultimately resulting in a full comprehension of innate
immunity effects on I/R injury. Such differences may explain why
NLRP32/2 deletion was beneficial in an in vivo model of kidney
I/R injury [12], probably as a result of decreased leucocyte
recruitment in the injured organ of the NLRP32/2 animal. A
recent study in the in vivo model of myocardial I/R injury also
demonstrated that inflammasome activation contributed to in vivo
I/R cardiac injury [41]. Ischemic preconditioning was however
not examined in that study. Further studies in an in vivo model
will be needed to answer these questions for the heart. The current
study has clearly demonstrated that for the heart only, ablation of
the innate immunity protein NLRP3 prevents cardiac IPC
signaling, probably through diminished cardiac IL-6/STAT3
signaling.
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